Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has provided an announcement.
NetraMark Holdings Inc., a premier AI company in the pharmaceutical industry, has secured a contract with a global biopharmaceutical company to support a Phase 3 clinical trial. This engagement highlights the growing trust in NetraAI’s precision analytics, which aims to enhance decision-making in late-stage trials by identifying patient subpopulations and analyzing treatment responses. The project signifies NetraMark’s expanding role in high-value clinical trials and reinforces its position as a key partner in optimizing clinical trial outcomes.
More about NetraMark Holdings
NetraMark is a leader in developing Generative Artificial Intelligence and Machine Learning solutions for the pharmaceutical industry. The company uses a unique topology-based algorithm to analyze patient data, enabling precise segmentation and classification of diseases and patient responses to treatments.
Average Trading Volume: 48,319
Technical Sentiment Signal: Hold
Current Market Cap: C$96.15M
See more insights into AIAI stock on TipRanks’ Stock Analysis page.